KRM Ayurveda Ltd(KRMAYURVED)

NSE: KRMAYURVED

₹ 238.8+2.47%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 508 crWebsite: www.krmayurvedaindia.com/Updated: 24 Oct 2026

About

KRM Ayurveda provides Ayurvedic healthcare services through hospitals and clinics, and it also makes and trades Ayurvedic products. Revenue from operations was ₹101.69 crore in FY26. Services made up about 54% of revenue in FY26, up from about 35% in FY25. The company runs six hospitals with 223 beds as of FY26.^[1][2][3]

Business segments

Sale of services brought in ₹5,468.05 lakhs in FY26, about 54% of revenue, up from about 35% in FY25.^[2][3]
Sale of products brought in ₹4,701.02 lakhs in FY26, about 46% of revenue. This was broadly stable against ₹4,923 lakhs in FY25.^[2][3][4]
Hospital and services revenue was ₹2,392.20 lakhs in Q1 FY27, up 109.8% year on year and 45.6% from the previous quarter.^[4]

Services and products

Healthcare services include Panchakarma, inpatient (IPD) and outpatient (OPD) care, yoga, diet and acupressure.^[2]
The products cover kidney and liver health, digestive care, skin wellness, and stress and lifestyle management.^[2]
Top-selling products include Supra Neph, KRM Renplus, Karma KFT, Karma T Renal, Neph Tablet, Nutriment-K, Karma CP, Shothnil Tablet, Soma Capsule and K-Calm.^[2]
As of FY26, 300 approved SKUs were waiting to be launched through e-commerce and a larger clinic network.^[3]

Facilities and capacity

As of FY26, the company ran six hospitals with 223 beds, plus several clinics, and had more than 40 doctors.^[3]
Hospitals have been added in Pithampura, Delhi, Gurgaon and Jaipur. Other hospital locations include Lucknow and Udaipur.^[3]
The company added 103 beds in FY27 up to the Q1 FY27 call.^[4]
Products are made at a GMP-certified production unit.^[2]

Key operating numbers

Overall bed occupancy was 69% in FY26. Occupancy was above 90% at the older Delhi and Gurgaon hospitals and 35-40% at the newer Jaipur, Lucknow and Udaipur hospitals.^[3]
Average revenue per occupied bed was ₹8,400 per day in FY26.^[3]
Management estimates the 103 beds added so far in FY27 could bring about ₹25 cr of extra annual inpatient (IPD) revenue.^[4]

Customers and distribution

Government business makes up a large part of the services segment, including empanelment with the Ministry of Defence as a three-year pilot.^[3]
The older hospitals are empanelled with corporates including Hero Motors, Maruti and Honda.^[3]
Management expects related-party sales to Karma Life Care LLC to grow to as much as ₹25 crore in FY27.^[2]
The company has more than 8 lakh YouTube subscribers across three channels, as of Q1 FY27.^[4]

Expansion plans

The company plans to grow from about 235 beds to about 500 beds in FY27, including a 100-bed hospital in Gurgaon for which an agreement has been signed.^[3]
Over three years, the company aims for 1,500-2,000 beds and about 100 super-specialty clinics across India.^[3]
The company plans to add 30 super-specialty clinics in FY27. Four were added after the IPO, including Dwarka and Janakpuri in Delhi, with Navi Mumbai coming up.^[3]
The company's own direct-to-consumer online store is scheduled to go live in Q2 FY27, alongside listings on 1mg and other national marketplaces.^[4]
A luxury Ayurveda hospital in Delhi, starting with about 25 beds, and a 500-seat telemedicine centre are planned.^[3]

Recent developments

The IPO on NSE Emerge was oversubscribed 74 times. The proceeds were used to repay all debt, according to the Q4 FY26 call.^[3]
₹30.45 crore of IPO money had not been used as of FY26 and was held in fixed deposits.^[2]
The company opened a 3,000 sq. ft. day care centre in Ghaziabad, Uttar Pradesh, on 23 September 2026.^[5]
The managing director's proposed pay is ₹144 lakhs a year, up from ₹84 lakhs, according to the FY26 annual report.^[2]

Market Cap

₹508 Cr

High / Low

₹344 / 156

Stock P/E

27.9

Price / Book

4.9

Book Value

₹54

EPS

₹9.5

No. of Shares

2.13 Cr

ROCE

26.1%

ROE

17.5%

OPM

29.3%

Debt / Equity

0.00

Sales

₹102 Cr

Net Profit

₹20 Cr

Promoter holding

69.3%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials